荷尔蒙避孕药市场规模、份额、成长分析（按产品、按激素、按年龄、按最终用户、按地区）- 产业预测，2025 年至 2032 年

2023 年全球荷尔蒙避孕药市场规模价值 193 亿美元，预计将从 2024 年的 201.1 亿美元增长到 2032 年的 279.5 亿美元，预计在预测期内（2025-2032 年）到 2032 年将达到 202.9 亿美元)。

全球荷尔蒙避孕药市场预计将大幅成长，预计 2022 年至 2030 年的复合年增长率约为 4.5%。这种增长主要是由于人们对避孕方法的认识和接受度不断提高、性行为感染感染（STI）盛行率不断上升以及对有效计划生育解决方案的需求不断增加。口服避孕药因其有效性和便利性而占据市场主导地位，尤其是含有雌激素和黄体素的复方药。然而，由于仅含孕激素的避孕药非常适合无法使用雌激素的女性且副作用较少，因此越来越受欢迎，因此预计未来其成长将会加速。由于性传染​​感染预防的局限性，同时使用保险套仍然很重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

荷尔蒙避孕药市场规模（依产品划分）

• 市场概况
• 口服避孕药
• 注射避孕药
• 事后紧急避孕药
• 避孕环
• 经皮吸收贴片

荷尔蒙避孕市场规模（依荷尔蒙分列）

• 市场概况
• 仅含黄体素的避孕药
• 合併荷尔蒙避孕药

荷尔蒙避孕药市场规模（依年龄划分）

• 市场概况
• 15-24岁
• 25-34岁
• 35-44岁
• 年龄 44 岁或以上

荷尔蒙避孕药市场规模（以最终用户划分）

• 市场概况
• 医院
• 适合家庭使用
• 诊所

荷尔蒙避孕药市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（USA）
• Viatris Inc.（USA）
• Organon & Co.（USA）
• Mithra Pharmaceuticals（Belgium）
• Agile Therapeutics, Inc.（USA）
• Mayne Pharma Group Limited（Australia）
• Afaxys, Inc.（USA）
• Pregna International Ltd.（India）
• Lupin Pharmaceuticals Inc.（India）
• Cipla Limited（India）
• Sun Pharmaceutical Industries Limited（India）
• Piramal Enterprises Limited（India）

结论和建议

Global Hormonal Contraceptive Market size was valued at USD 19.3 billion in 2023 and is poised to grow from USD 20.11 billion in 2024 to USD 27.95 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The global hormonal contraceptive market is poised for significant growth, projected to expand at a compound annual growth rate (CAGR) of around 4.5% between 2022 and 2030. This growth is largely fueled by increasing awareness and acceptance of contraceptive methods, a rising incidence of sexually transmitted infections (STIs), and heightened demand for effective family planning solutions. Oral contraceptives dominate the market, particularly combination pills that contain both estrogen and progestin, thanks to their effectiveness and convenience. However, progestin-only pills are gaining traction, anticipated to grow faster due to their minimal side effects, making them ideal for women who cannot use estrogen. Given their limitations in preventing STIs, the concurrent use of condoms remains crucial for protection.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segmental Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

A significant driver of the global hormonal contraceptive market is the rising awareness and acceptance of contraception for family planning purposes. As population levels continue to surge, especially in developing nations, there is an escalating demand for reliable birth control solutions that enable couples to control family size and spacing effectively. This growing recognition of the importance of contraception has resulted in a notable uptick in the utilization of hormonal contraceptives, which are celebrated for their high efficacy in preventing unintended pregnancies while providing a user-friendly and reversible option for individuals seeking to manage their reproductive health.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable constraints due to various social and cultural factors that hinder women's access to contraceptive methods. In numerous cultures and communities, contraception is often stigmatized, and certain religious doctrines explicitly forbid its use. Furthermore, a significant lack of awareness and education surrounding contraceptive options exists in many areas globally, contributing to diminished demand for such products. These intertwined social and cultural influences can significantly impede market growth, particularly in regions where such factors heavily influence the choices regarding contraceptive usage. Addressing these challenges is crucial for expanding access to hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a pronounced shift towards Long-Acting Reversible Contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal implants, reflecting a significant trend among consumers. These methods offer high efficacy in preventing unintended pregnancies while providing extended duration of use, appealing particularly to younger women and those desiring reliable, low-maintenance contraception. This growing preference is driven by increasing awareness of reproductive health options, enhanced convenience, and the desire for a hassle-free experience. As a result, LARCs are rapidly gaining traction, reshaping the landscape of hormonal contraceptive solutions worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2025-2032)

• Market Overview
• Oral Contraceptive Pills
• Injectable Birth Control
• Emergency Contraceptive Pills
• Vaginal Rings
• Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2025-2032)

• Market Overview
• Progestin Only Contraceptive
• Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2025-2032)

• Market Overview
• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Household
• Clinics

Global Hormonal Contraceptive Market Size & CAGR (2025-2032)

• North America (Product, Hormones, End User, Age)
  • US
  • Canada
• Europe (Product, Hormones, End User, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Hormones, End User, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Hormones, End User, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Hormones, End User, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations